WuXi Biologics and Adagene announce a strategic development and manufacturing partnership
WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Adagene Inc., an emerging biotech company engaged in discovery and development of innovative antibody therapeutics for the global market, announced a strategic collaboration agreement on March 9. According to the agreement, WuXi Biologics will provide Adagene with production technology services to accelerate its declaration process of product pipeline in the United States Food and Drug Administration (FDA) and the national food and Drug Administration (CFDA) approval process.
Adagene is building a global biotech company with an internal pipeline of antibody therapeutics focused on complex antigens, and therapeutic candidates with enhanced biophysical properties. The collaboration with WuXi Biologics will support supply of Adagene’s products for clinical trials under Investigational New Drug (IND) applications in both China and United States.
“The strategic collaboration with WuXi Biologics will enable Adagene to focus on its core competency in the discovery of novel antibody therapeutics. Additionally, by leveraging on the process development and manufacturing capabilities of WuXi Biologics, Adagene’s next wave of innovative products will be accelerated into the clinic,” said Dr. Peter Luo, Co-Founder and CEO of Adagene.
“We are pleased to work closely with Adagene in development and manufacturing of some urgently-needed antibody therapeutics through the world-class, high-quality biological drug platform at WuXi Biologics,” said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics.
“The collaboration is expected to introduce the world-class life-saving biologics to the Chinese market, thereby benefiting patients worldwide.
Adagene was co-founded by two serial entrepreneurs to power antibody discovery. Its aim is to become the leading player in antibody discovery and engineering. It has developed a proprietary dynamic precision library (DPL) and is showcasing the power of the library with a unique pipeline of innovative antibody therapeutics that are advancing into clinical trials. Adagene has completed two series of financing, raising over $36 million. Investors include F-Prime Capital (formerly Fidelity Biosciences), Eight Roads Ventures China (formerly Fidelity Growth Partners Asia), 6 Dimensions Capital, GP Healthcare Capital and New World TMT. For more information, please visit www.adagene.com.
About WuXi Biologics
Listed in Hong Kong,WuXi Biologics, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.